Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Zevra Therapeutics (ZVRA) Net Margin (2016 - 2025)

Historic Net Margin for Zevra Therapeutics (ZVRA) over the last 9 years, with Q3 2025 value amounting to 2.08%.

  • Zevra Therapeutics' Net Margin rose 8958900.0% to 2.08% in Q3 2025 from the same period last year, while for Sep 2025 it was 41.85%, marking a year-over-year increase of 4079100.0%. This contributed to the annual value of 446.85% for FY2024, which is 2791600.0% down from last year.
  • As of Q3 2025, Zevra Therapeutics' Net Margin stood at 2.08%, which was up 8958900.0% from 288.44% recorded in Q2 2025.
  • Over the past 5 years, Zevra Therapeutics' Net Margin peaked at 288.44% during Q2 2025, and registered a low of 1849.38% during Q2 2022.
  • Its 5-year average for Net Margin is 316.87%, with a median of 230.2% in 2022.
  • Its Net Margin has fluctuated over the past 5 years, first tumbled by -17601600bps in 2022, then surged by 18190100bps in 2023.
  • Over the past 5 years, Zevra Therapeutics' Net Margin (Quarter) stood at 104.69% in 2021, then tumbled by -326bps to 446.14% in 2022, then skyrocketed by 65bps to 153.96% in 2023, then crashed by -93bps to 297.53% in 2024, then soared by 99bps to 2.08% in 2025.
  • Its Net Margin stands at 2.08% for Q3 2025, versus 288.44% for Q2 2025 and 15.19% for Q1 2025.